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The goals for treatment of eosinophilic esophagitis (EoE) are improvements in symptoms 
and esophageal eosinophilic inflammation with the ideal endpoint complete resolution of the 
latter.1 Once a diagnosis of proton pump inhibitor (PPI)-nonresponsive EoE is confirmed, 
treatment options include pharmacologic agents and/or dietary elimination. If pharmacologic 
therapy is chosen, topical CSs are effective and considered first line. Although these 
medications are currently not Food and Drug Administration approved for EoE, the 2 
commonly used options are swallowed aerosolized FP and OVB. Systemic CSs (ie, 
prednisolone and methylprednisolone) may be useful if topical steroids are not effective or 
in patients who require rapid improvement in symptoms.
This article discusses the use of topical and systemic CSs for induction of remission and as 
maintenance treatment of pediatric EoE. The risks and benefits of these agents are outlined 
and some important and clinically relevant questions discussed.
TOPICAL CORTICOSTEROIDS FOR INDUCTION
In 1998, Faubion and colleagues2 described 4 children with eosinophilic inflammation 
isolated to the esophagus who improved clinically and histologically by swallowing 
aerosolized CSs (FP and beclomethasone) from an inhaler without use of a spacer. Over 
time, FP has become the topical CS used most often in EoE, although other agents are also 
used (discussed later). We will review prospective and randomized studies involving topical 
steroids used in pediatric eosinophilic esophagitis (Table 1). Adult studies are discussed 
elsewhere in this issue.
Fluticasone
In 2002, a prospective study using swallowed FP in children cited its ease of administration, 
low systemic absorption, and rapid first-pass metabolism by the liver to limit systemic side 
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effects.3 These children had symptoms of esophageal dysfunction (ie, chest pain, food 
impaction, dysphagia, feeding refusal, and vomiting), eosinophilic esophageal infiltration, 
normal 24-hour continuous monitoring of intraesophageal pH (pH probe), and lack of 
clinical response to an 8-week trial of PPI. FP dosing was age dependent, with a maximum 
of 880 mg/d divided twice daily. Four patients had no food allergens identified by history, 
radioimmunosorbent assay, or skin prick testing and were started directly on swallowed FP. 
Eleven patients were started on dietary restriction and nutritional counseling based on 
abnormal allergy testing or history; however, none of these patients had clinical 
improvement and 9 were subsequently treated with swallowed FP. All 13 patients who 
received FP had resolution of their presenting symptoms, and all 11 patients with post-
treatment endoscopy showed improvement in histology with similar decreases in 
eosinophilia in proximal and distal esophageal biopsies.
A subsequent randomized, double-blind, placebo-controlled trial in children showed that 
50% of FP-treated patients achieved complete histologic remission (≤1 eosinophil [EOS] per 
high-power field [HPF]) with a standard dose, regardless of patient age and/or size, of 880 
mg/d divided twice daily.4 Patient factors predictive of histologic resolution in this study 
included shorter stature and younger age. Unlike the previous study, proximal esophageal 
biopsies were more improved than those from the distal esophagus. Another randomized 
controlled trial comparing swallowed FP to oral prednisone (880–1760 mg/d based on age 
and 1 mg/kg/d to a maximum of 30 mg twice daily, respectively) showed complete 
histologic resolution in 50% of patients in FP group versus 81% in prednisone group at week 
4; partial improvement in histologic grade was recorded in 94% of patients in both groups.5 
As expected, symptomatic improvement was seen more often compared with histologic 
reversal; 97.2% of FP patients and 100% of prednisone patients had resolution of presenting 
symptoms with therapy although symptoms recurred in approximately 45% of patients 12 
weeks after treatment was stopped (Fig. 1A).
A recent prospective Italian study in children using a higher dose of FP (2250 mg/d) for 6 
weeks reported higher likelihood (73.5%) in reaching post-treatment peak esophageal 
eosinophils of less than 6 eos/hpf and suggested that more severe esophageal inflammation 
(higher median peak eos/hpf, presence of eosinophilic abscesses, and peak mast cells/HPF) 
was associated with higher response rate to FP treatment.6 Age and height did not affect 
response in this study.
Improvement in incidental gastric eosinophilic inflammation (≥10 eos/hpf) in patients 
otherwise similar to EoE patients was noted with FP.7 Therefore, mild gastric eosinophilia 
should not exclude FP as a possible therapeutic option for esophageal eosinophilia.
The results of the first double-blind, randomized, placebo-controlled trial of FP (1760 mg/d) 
in children and adults are awaited.8 Further studies are needed to determine ideal dosing 
regimen but current recommendations are listed in Table 2.
Budesonide
Budesonide is another topical steroid with proved efficacy for EoE. OVB was initially 
developed to help patients who were developmentally unable to perform the puff and 
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swallow technique required for FP. The first studies to evaluate its efficacy mixed aqueous 
budesonide (0.5 mg/2 mL suspension, Budesonide Respules [Pulmicort], Astra-Zeneca, 
Wilmington, DE) with sucralose (see Table 2 for recipe) to create a thickened slurry. A 
randomized, double-blind, placebo-controlled trial in children showed significant 
improvement in symptoms, endoscopic findings, and esophageal eosinophilia compared with 
placebo.9 Patients less than 1.5 meters (5 feet) tall received 1 mg daily; patients greater than 
or equal to 5 feet tall received 2 mg daily for 3 months. Patients in both groups also received 
twice-daily lansoprazole (15 mg twice daily if less than 10 years old and 30 mg twice daily 
if greater than 10 years old). Peak eosinophil counts in the OVB group improved from 66.7 
to 4.8 eos/hpf, with significant reductions in proximal, mid-, and distal esophageal 
eosinophilia.
No studies to date have compared FP and OVB in children.
Ciclesonide
Two small case series report a total of 8 children treated with ciclesonide, a topical CS also 
used in asthma, allergic rhinitis, and allergic conjunctivitis.10,11 Six of the 8 patients showed 
histologic improvement; the 2 who did not respond had previous poor response to OVB as 
well. In asthma, inhaled ciclesonide seems to have similar effectiveness compared with 
inhaled FP and nebulized budesonide.12 Larger randomized, drug-controlled studies are 
needed to see if this is the case in EoE.
TOPICAL CORTICOSTEROIDS FOR MAINTENANCE THERAPY
EoE is considered a chronic immune-mediated disease, yet long-term management has not 
been defined. Need for maintenance therapy is underscored by the observations that 45% of 
children had recurrence of symptoms within 12 weeks of discontinuing CS therapy5 and 
esophageal eosinophilia recurred in a majority of patients13 after 6 months off therapy (see 
Fig. 1). Straumann and colleagues14 prospectively evaluated a maintenance regimen with 
swallowed nebulized budesonide (0.5 mg/d), in adolescents and adults after successful 
remission with 15 days of nebulized budesonide (2 mg/d). Patients placed on maintenance 
therapy of nebulized budesonide (0.5 mg/d) had increased eosinophil load compared with at 
remission/end of induction (31.8 to 0.4 eos/hpf, respectively). This increase was less 
pronounced when compared with patients placed on placebo after remission/end of 
induction (65.0 to 0.7 eos/hpf, respectively). Symptom scores were stable with maintenance 
therapy but increased with placebo. This study not only highlighted a shorter induction time 
of 15 days but also a newer mode of delivery (ie, via a nebulizer). Further studies with 
higher maintenance dose are needed to evaluate for efficacy and long-term adverse effects.
Maintenance therapy studies have not been done with FP or OVB or in children.
OTHER DELIVERY METHODS
Fluticasone
A tablet form (1.5 mg and 3 mg) of fluticasone is currently undergoing phase 1/2a trials in 
adolescents and adults.15
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Budesonide
The current OVB formulation contains 10 mg sucralose per 1 mg budesonide to create an 8-
mL slurry.16 Concerns about taste, cost, and potential adverse effects of sucralose have made 
many patients and parents wary of OVB.17 Some patients may use applesauce or other 
palatable food products that patients are not allergic to, although efficacy with these alternate 
vehicles has not been studied. At the authors’ institution, 1 to 2 tablespoons of applesauce 
are allowed to be mixed with 2 respules (0.5 mg/2 mL) of budesonide. Hait and colleagues18 
found that 13 of 14 patients who added a hypoallergenic, amino acid–based semisolid 
(Neocate Nutra, Nutricia, Gaithersburg, MD) to their budesonide respules improved with 
post-treatment eosinophil counts less than 15 eos/hpf and continue to find results that are at 
least comparable to OVB with improved patient compliance (Eitan Rubinstein, personal 
communication, 2013).
Also in the works is a non–sucralose-based oral budesonide suspension (OBS) currently 
being studied in adolescents and adults. A prospective, randomized, double-blind, placebo-
controlled study comparing 2 doses of OBS and placebo in children ages 2 to 18 years found 
panesophageal endoscopic and histologic dose-related responses.19 Histologic response 
(peak 6 eos/hpf) was seen in 94% of patients in the high-dose OBS group (1.4 mg twice 
daily for 2–9 years old and 2 mg twice daily for 10–18 years old) versus 54% of patients in 
the medium-dose group (1.4 mg daily for 2–9 years old and 2 mg daily for 10–18 years old) 
and 5.6% in the placebo arm. This higher response in the high-dose group suggests a 
possible need to increase OVB dosing regimens to a higher dose of 4 mg/d in patients 
previously thought to fail budesonide therapy.
SYSTEMIC CORTICOSTEROIDS
Oral prednisone was the first pharmacologic agent shown effective in treating EoE20 but can 
have systemic adverse effects in 40% of patients.5 Although complete histologic resolution 
is more likely with prednisone compared with FP, the symptom improvement and long-term 
disease remissions were similar to those with FP. With the newer therapies available, 
systemic prednisone is now reserved for urgent situations where topical CS may not be as 
rapidly effective. Intravenous methylprednisolone may be considered in situations where 
patients are not tolerating anything by mouth.
MARKERS OF RESPONSE
The mechanism of action of topical steroids in EoE is still unknown. In randomized trials in 
children, 50% to 94% of children with EoE have partial to complete response to FP or OVB 
treatment.4,5,9 Interpretation of published data is challenging for a variety of reasons, 
including varying definitions of response, type of CS, CS formulation, mode of delivery, 
total daily dose, number of doses per day, and adjustment of dose for clinical factors, such as 
age and height (discussed later). Currently, predicting who will or will not respond to CSs is 
not possible, but some studies have identified possible mechanisms of nonresponsiveness in 
these patients.
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Caldwell and colleagues21 provided evidence that topical CSs directly affect esophageal 
epithelial gene expression in vivo. They identified 32 transcripts altered by FP treatment in 
responders compared with those with untreated EoE and normal healthy controls. One of the 
genes, FK506 binding protein 51 (FKBP51), a known steroid-induced gene in respiratory 
epithelial cells and lymphocytes, was increased in FP responders and found to act as a 
negative regulator of FP action. In vitro, increased baseline FKBP51 levels correlated with a 
decreased ability of glucocorticoid to repress interleukin 13–mediated eotaxin-3 promoter 
activity and may suggest a mechanism for steroid nonresponsiveness.
Responders to OVB (defined as patients who had <7 eos/hpf after therapy) show a decrease 
in lamina propria fibrosis score, esophageal fibrosis mediators (transforming growth factor 
b1 [TGF-b1] and phosphorylated Smad2/3), epithelial edema, and vascular cell adhesion 
molecule 1–positive vessels not seen in nonresponders oruntreated patients.22 This study 
also suggested that genetic polymorphisms in the TGF-b1 promoter may be predictive of CS 
responsiveness.
Medication delivery method could affect histologic response; a recent adult study showed 
higher mucosal medication contact time and improved eosinophil counts with OVB versus 
the nebulized budesonide method.23 Potential noninvasive markers for topical steroid 
therapy response include serum eosinophil cationic protein and serum eosinophil-derived 
neurotoxin.24,25
BENEFITS
A major benefit to patients of treatment with topical CS, in addition to improving their EoE, 
is not having to implement dietary modifications. As demonstrated in the recently validated 
PedsQL EoE Module, patients on restricted diets (and their parents) reported lower quality-
of-life scores, with the largest gaps concerning food, eating, and food feelings.26 Therefore, 
optimizing current topical CS therapy and developing other medical therapies are important 
in maintaining good quality of life for these patients. Nevertheless, a variety of elimination 
diets are also recommended as first-line therapy for EoE; practice at the authors’ institution 
is shown in Fig. 2. An adult study has shown symptomatic improvement with leukotriene 
antagonists but no effect on esophageal eosinophilia.27 The authors do not note this 
improvement, however, in clinical practice where patients on montelukast (for their asthma 
management) have active EoE. In addition, cysteinyl leukotriene levels in esophageal 
mucosal biopsies of children with EoE were similar to those of controls.28 A small series of 
children with EoE had no symptomatic or histologic response to cromolyn sodium.13
RISKS
As expected, 40% of children treated with prednisone for EoE exhibit systemic side effects, 
such as hyperphagia and weight gain.5 Up to 15% of patients receiving FP may develop 
esophageal candidiasis, although this is usually found incidentally on follow-up endoscopy, 
is not associated with esophageal inflammation, and may not be of clinical significance.4-6 
To minimize this risk, the authors instruct patients to not eat or drink for 30 minutes after 
drug administration and then drink a small amount of liquid to wash the esophageal mucosa 
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(see Table 2 for FP and OVB dosing regimens and instructions). The incidence of 
esophageal candidiasis is decreasing with careful attention to drug administration.
There has been no definitive evidence of adrenal suppression with topical steroids. In the 
placebo-controlled trial with OVB there were no signs of adrenal suppression; serum cortisol 
levels were similar between pretreatment, post-treatment, and placebo-groups.9 Long-term 
data regarding bone disease and/or growth rates are not yet available in patients with EoE. 
Asthma studies indicate that children receiving inhaled steroids grow 1 to 2 cm less than 
their counterparts; this height deficit does not accumulate but does persist into adulthood.
29,30
 Prospective long-term studies using large EoE patient databases are needed to evaluate 
this.31,32
SUMMARY AND UNMET NEEDS
Swallowed FP and OVB are effective first-line pharmacologic therapies for EoE and an 
alternative to dietary restrictions. Side effects are minimal without evidence of Cushing 
syndrome, as seen in treatment with systemic CSs. Recent preliminary studies suggest that 
higher dosing and/or improved delivery may be needed to improve efficacy of these 
medications.19 New studies on alternative delivery systems and different CSs (eg, 
ciclesonide) are encouraging. As knowledge of EoE expands, newer questions arise. Several 
of these are listed, recognizing that some have partial answers and others are without any 
answers at present. The authors hope this list will stimulate interests in the study of EoE:
1. Do the various formulations of topical CSs differ in efficacy and/or side-effect 
profile?
2. What are the optimal delivery mechanisms, dose strength, and dosing 
frequencies for topical CSs for induction and maintenance of remission?
3. What is the best length of treatment to induce remission?
4. What are long-term side effects of prolonged topical CS therapy (eg, linear 
growth, bone health, and adrenal suppression)? Are these adverse effects 
reversible or irreversible?
5. To what degree are adverse effects modified by simultaneous use of topical CSs 
for other conditions (eg, asthma and allergic rhinitis)?
6. Is there a benefit to cooling down the inflamed esophageal strictures with topical 
CSs or diet elimination prior to dilation?
7. Are CSs useful in the burnt-out esophagus without active eosinophilic 
inflammation but poor motility/compliance due to their effects on the fibrotic 
pathway?
8. Could PPI, mast cell stabilizers, or leukotriene antagonists be additive or 
synergistic with CS?
9. Should topical CSs be used in combination with diet and/or dilation therapy?
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KEY POINTS
• Topical corticosteroids (CSs) (eg, swallowed fluticasone propionate [FP] and 
oral viscous budesonide [OVB]) are effective first-line therapies for pediatric 
eosinophilic esophagitis.
• Topical CSs have minimal known side effects when used for treatment of 
eosinophilic esophagitis.
• Systemic CSs have significant adverse effects and are now reserved for urgent 
situations where topical CSs are not effective or in patients who require rapid 
improvement in symptoms.
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Fig. 1. 
(A) Proportion of symptom-free patients with prednisone and swallowed fluticasone. 
Patients received induction dose × 4 weeks, were weaned over 8 weeks, and were clinically 
monitored for next 12 weeks. (B) Recurrence of esophageal eosinophilia after withdrawal of 
swallowed fluticasone (220 mg twice daily). (From [A] Schaefer ET, Fitzgerald JF, 
Molleston JP, et al. Comparison of oral prednisone and topical fluticasone in the treatment of 
eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol 
2008;6:165–73, with permission; and [B] Liacouras CA, Spergel JM, Ruchelli E, et al. 
Eosinophilic esophagitis: a 10-year experience in 381 children. Clin Gastroenterol Hepatol 
2005;3:1202, with permission.)
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Fig. 2. 
Proposed algorithm for treatment of EoE.
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